DE60118206D1 - Antikonvulsive derivate zur behandlung und vorbeugung der entwicklung von typ ii diabetes und syndrom x - Google Patents

Antikonvulsive derivate zur behandlung und vorbeugung der entwicklung von typ ii diabetes und syndrom x

Info

Publication number
DE60118206D1
DE60118206D1 DE60118206T DE60118206T DE60118206D1 DE 60118206 D1 DE60118206 D1 DE 60118206D1 DE 60118206 T DE60118206 T DE 60118206T DE 60118206 T DE60118206 T DE 60118206T DE 60118206 D1 DE60118206 D1 DE 60118206D1
Authority
DE
Germany
Prior art keywords
diabetes
syndrome
treating
development
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60118206T
Other languages
English (en)
Other versions
DE60118206T2 (de
Inventor
Carlos Plata-Salaman
Jeffrey Crooke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceuticals Inc
Original Assignee
Ortho McNeil Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho McNeil Pharmaceutical Inc filed Critical Ortho McNeil Pharmaceutical Inc
Application granted granted Critical
Publication of DE60118206D1 publication Critical patent/DE60118206D1/de
Publication of DE60118206T2 publication Critical patent/DE60118206T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60118206T 2000-07-07 2001-07-06 Antikonvulsive derivate zur behandlung und vorbeugung der entwicklung von typ ii diabetes und syndrom x Expired - Lifetime DE60118206T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US21714100P 2000-07-07 2000-07-07
US217141P 2000-07-07
US27002201P 2001-02-20 2001-02-20
US270022P 2001-02-20
PCT/US2001/021404 WO2002003984A2 (en) 2000-07-07 2001-07-06 Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x

Publications (2)

Publication Number Publication Date
DE60118206D1 true DE60118206D1 (de) 2006-05-11
DE60118206T2 DE60118206T2 (de) 2006-12-14

Family

ID=26911655

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60118206T Expired - Lifetime DE60118206T2 (de) 2000-07-07 2001-07-06 Antikonvulsive derivate zur behandlung und vorbeugung der entwicklung von typ ii diabetes und syndrom x

Country Status (22)

Country Link
US (2) US6852701B2 (de)
EP (1) EP1309324B1 (de)
JP (1) JP4920163B2 (de)
CN (1) CN101404993A (de)
AR (1) AR032465A1 (de)
AT (1) ATE320805T1 (de)
AU (1) AU2001280486A1 (de)
BR (1) BR0112519A (de)
CA (1) CA2415093A1 (de)
DE (1) DE60118206T2 (de)
DK (1) DK1309324T3 (de)
ES (1) ES2260261T3 (de)
HU (1) HUP0302307A3 (de)
IL (1) IL153713A0 (de)
MX (1) MXPA03000136A (de)
MY (1) MY126897A (de)
NO (1) NO20030064L (de)
NZ (1) NZ523531A (de)
PL (1) PL365680A1 (de)
PT (1) PT1309324E (de)
RU (1) RU2268720C2 (de)
WO (1) WO2002003984A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US20080255093A1 (en) * 1999-06-14 2008-10-16 Tam Peter Y Compositions and methods for treating obesity and related disorders
US7674776B2 (en) * 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7208477B2 (en) 2002-12-02 2007-04-24 University Of Florida Research Foundation, Inc. Treatments for benign tumors, cancers, neoplasias, and/or other inflammatory disorders or diseases
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
AR049646A1 (es) * 2004-06-16 2006-08-23 Janssen Pharmaceutica Nv Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
WO2006023861A1 (en) * 2004-08-24 2006-03-02 Janssen Pharmaceutica N.V. Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents
CN101754947A (zh) * 2005-05-20 2010-06-23 詹森药业有限公司 磺酰胺衍生物的制备方法
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070191461A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of migraine
US20070191449A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Depression
US20070191453A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-heteroaryl sulfamide derivatives for the treatment of substance abuse and addiction
US20070191459A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of Benzo-Heteroaryl Sulfamide Derivatives for Lowering Lipids and Lowering Blood Glucose Levels
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
TW200812573A (en) * 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
WO2008027557A2 (en) 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
ES2312308T3 (es) 2006-11-17 2013-03-26 Supernus Pharmaceuticals, Inc. Formulaciones de liberación sostenida de topiramato
CN101553204B (zh) * 2006-12-04 2013-10-30 苏佩努斯制药公司 托吡酯的增强的立即释放制剂
CA2676051C (en) 2007-01-25 2017-06-06 Verva Pharmaceuticals Ltd Insulin sensitisers and methods of treatment
US20090076128A1 (en) * 2007-09-15 2009-03-19 Protia Llc Deuterium-enriched topiramate
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US8580298B2 (en) * 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
EA018567B1 (ru) 2008-06-23 2013-08-30 Янссен Фармацевтика Нв Кристаллическая форма (2s)-(-)-n-(6-хлор-2,3-дигидробензо[1,4]диоксин-2-илметил)сульфамида
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
CN102579367B (zh) 2012-03-23 2014-03-12 中国人民解放军军事医学科学院毒物药物研究所 托吡酯缓释药物组合物、其制备方法及用途
EP2829270B1 (de) 2012-03-23 2020-11-11 Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China Verbindungsprodukt mit synephrin und topiramat
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10278948B1 (en) 2015-09-03 2019-05-07 Tian Xia Method for transnasal delivery of anticonvulsant and therapeutic treatments

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
IL103172A (en) 1991-09-19 1997-01-10 Mcneilab Inc Preparation of chlorosulfate and sulfamate derivatives of 2, 3:4, 5-bis-o-(1-methylethylidene)-beta-d-fructopyranose and (1-methylcyclohexyl) methanol
US5242942A (en) 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
EP0915697B1 (de) 1996-06-28 2002-09-18 Ortho-McNeil Pharmaceutical, Inc. Antikonvulsive sulfamatderivate zur behandlung von fettleibigkeit
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
KR100697485B1 (ko) 1999-02-24 2007-03-20 유니버시티 오브 신시내티 충동 자제 이상 치료를 위한 설파메이트 유도체의 용도
JP2003530300A (ja) 1999-04-08 2003-10-14 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 体重低下を維持することに有用な抗痙攣薬誘導体
CA2369093C (en) 1999-04-08 2005-10-18 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in lowering lipids
NZ514811A (en) * 1999-04-08 2005-01-28 Ortho Mcneil Pharm Inc Anticonvulsant derivatives useful in reducing blood glucose levels
ES2542891T3 (es) 1999-06-14 2015-08-12 Vivus, Inc. Terapia de combinación para el tratamiento de apnea del sueño asociada con la obesidad

Also Published As

Publication number Publication date
DE60118206T2 (de) 2006-12-14
PT1309324E (pt) 2006-06-30
EP1309324B1 (de) 2006-03-22
CA2415093A1 (en) 2002-01-17
HUP0302307A3 (en) 2007-05-29
NO20030064L (no) 2003-03-06
US20040209824A1 (en) 2004-10-21
AR032465A1 (es) 2003-11-12
CN101404993A (zh) 2009-04-08
MY126897A (en) 2006-10-31
US20020037861A1 (en) 2002-03-28
JP2004510700A (ja) 2004-04-08
PL365680A1 (en) 2005-01-10
DK1309324T3 (da) 2006-06-12
BR0112519A (pt) 2004-03-30
HUP0302307A2 (hu) 2003-10-28
EP1309324A2 (de) 2003-05-14
JP4920163B2 (ja) 2012-04-18
US6852701B2 (en) 2005-02-08
ES2260261T3 (es) 2006-11-01
NZ523531A (en) 2005-07-29
WO2002003984A3 (en) 2003-03-06
NO20030064D0 (no) 2003-01-06
ATE320805T1 (de) 2006-04-15
RU2268720C2 (ru) 2006-01-27
WO2002003984A2 (en) 2002-01-17
AU2001280486A1 (en) 2002-01-21
US7109174B2 (en) 2006-09-19
MXPA03000136A (es) 2004-09-13
IL153713A0 (en) 2003-07-06

Similar Documents

Publication Publication Date Title
DE60118206D1 (de) Antikonvulsive derivate zur behandlung und vorbeugung der entwicklung von typ ii diabetes und syndrom x
DE60109044D1 (de) Arzneimittel zur behandlung der mucositis, stomatitis und des behcetschen syndroms
ATE305306T1 (de) Reboxetin zur behandlung von peripheren neuropathien
NO20031923D0 (no) Ny behandling av "restless legs" syndrom
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE269303T1 (de) Arylpiperazinyl-cyclohexyl indolderivate zur behandlung von depressionen
DE60042984D1 (de) Arzneitmittel zur Behandlung von Duchenne-Muskeldystrophie
ATE318138T1 (de) Pharmazeutisches mittel zur behandlung von diabetes
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
ATE336235T1 (de) (-)(3-trihalomethylphenoxy) (4-halophenyl) zur behandlung von insulinresistenz und typ ii diabetes
DE60045386D1 (de) Gerät zur thermischen behandlung von bandscheiben
DE60127277D1 (de) Zusammensetzung zur transdermalen und/oder transmukosalen Verabreichung von Wirkstoffen, die ausreichende therapeutische Spiegel garantiert
DE60021266D1 (de) Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine
EA200300025A1 (ru) Способ лечения патологического синдрома и лекарственное средство
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
FR2812875B1 (fr) Nouvelles diamines possedant une activite modulatrice des casr et leur mode de preparation
DE69806801D1 (de) Galenische präparation zur prävention und behandlung von hepatokarzinomen
DE60132600D1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
NO20023482D0 (no) Fremgangsmåte for behandling av stoffmisbruk
DE60139783D1 (de) Gen und pflanzenextrakte, wirksam zur behandlung und prävention von chlamydieninfektionen
ATE298569T1 (de) Virus behandlung
ATE234617T1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien

Legal Events

Date Code Title Description
8364 No opposition during term of opposition